GT201000101A - Productos quimioterapéuticos cristalinos - Google Patents
Productos quimioterapéuticos cristalinosInfo
- Publication number
- GT201000101A GT201000101A GT201000101A GT201000101A GT201000101A GT 201000101 A GT201000101 A GT 201000101A GT 201000101 A GT201000101 A GT 201000101A GT 201000101 A GT201000101 A GT 201000101A GT 201000101 A GT201000101 A GT 201000101A
- Authority
- GT
- Guatemala
- Prior art keywords
- crystal
- chemotherapeutic products
- chemotherapeutic
- products
- methylpenyl
- Prior art date
Links
- 230000000973 chemotherapeutic effect Effects 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98124307P | 2007-10-19 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201000101A true GT201000101A (es) | 2012-03-26 |
Family
ID=40242659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201000101A GT201000101A (es) | 2007-10-19 | 2010-04-16 | Productos quimioterapéuticos cristalinos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7943782B2 (ru) |
| EP (1) | EP2195297A1 (ru) |
| JP (1) | JP2011500706A (ru) |
| KR (1) | KR20100102098A (ru) |
| CN (1) | CN101827823B (ru) |
| AU (1) | AU2008312532A1 (ru) |
| BR (1) | BRPI0818343A2 (ru) |
| CA (1) | CA2699353A1 (ru) |
| CO (1) | CO6280483A2 (ru) |
| CR (1) | CR11386A (ru) |
| DO (1) | DOP2010000116A (ru) |
| GT (1) | GT201000101A (ru) |
| MX (1) | MX2010004289A (ru) |
| MY (1) | MY153098A (ru) |
| PA (1) | PA8800501A1 (ru) |
| RU (1) | RU2010119917A (ru) |
| SG (1) | SG185326A1 (ru) |
| UA (1) | UA99487C2 (ru) |
| WO (1) | WO2009052229A1 (ru) |
| ZA (1) | ZA201002092B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011329656B2 (en) | 2010-11-19 | 2017-01-05 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | DISPOSAL OF SMALL MOLECULES THROUGH AN IMPLANTABLE THERAPEUTIC DEVICE |
| US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| CA2957548A1 (en) | 2014-08-08 | 2016-02-11 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003232113A1 (en) * | 2002-05-10 | 2003-11-11 | Teva Pharmaceutical Industries Ltd. | Novel crystalline forms of gatifloxacin |
| KR20060028761A (ko) * | 2003-05-08 | 2006-04-03 | 아이박스 파마슈티컬스 에스.알.오. | 다형의 카베르골린 |
| US7297709B2 (en) * | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| PL1638941T3 (pl) * | 2003-05-22 | 2010-11-30 | Abbvie Bahamas Ltd | Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz |
| DE102005033100B3 (de) * | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
| WO2007015569A1 (ja) * | 2005-08-01 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を予測する方法 |
| US9006240B2 (en) * | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| CN101346128B (zh) | 2005-10-25 | 2013-10-02 | 雅培制药有限公司 | 包含低水溶解度药物的配方及其使用方法 |
| JP2009521493A (ja) * | 2005-12-23 | 2009-06-04 | アルコン，インコーポレイテッド | 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤 |
| US20070173490A1 (en) * | 2006-01-20 | 2007-07-26 | Lian Huang | Novel solid forms of (4R)-1-[2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5- tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid |
| WO2008055966A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
-
2008
- 2008-10-15 US US12/251,964 patent/US7943782B2/en not_active Expired - Fee Related
- 2008-10-16 AU AU2008312532A patent/AU2008312532A1/en not_active Abandoned
- 2008-10-16 MY MYPI20101652 patent/MY153098A/en unknown
- 2008-10-16 KR KR1020107010994A patent/KR20100102098A/ko not_active Withdrawn
- 2008-10-16 WO PCT/US2008/080066 patent/WO2009052229A1/en not_active Ceased
- 2008-10-16 EP EP08839149A patent/EP2195297A1/en not_active Withdrawn
- 2008-10-16 CA CA2699353A patent/CA2699353A1/en not_active Abandoned
- 2008-10-16 MX MX2010004289A patent/MX2010004289A/es active IP Right Grant
- 2008-10-16 JP JP2010530092A patent/JP2011500706A/ja active Pending
- 2008-10-16 SG SG2012078200A patent/SG185326A1/en unknown
- 2008-10-16 CN CN2008801119449A patent/CN101827823B/zh not_active Expired - Fee Related
- 2008-10-16 RU RU2010119917/04A patent/RU2010119917A/ru not_active Application Discontinuation
- 2008-10-16 BR BRPI0818343A patent/BRPI0818343A2/pt not_active IP Right Cessation
- 2008-10-16 UA UAA201005821A patent/UA99487C2/ru unknown
- 2008-10-17 PA PA20088800501A patent/PA8800501A1/es unknown
-
2010
- 2010-03-24 ZA ZA2010/02092A patent/ZA201002092B/en unknown
- 2010-04-16 DO DO2010000116A patent/DOP2010000116A/es unknown
- 2010-04-16 GT GT201000101A patent/GT201000101A/es unknown
- 2010-04-23 CR CR11386A patent/CR11386A/es not_active Application Discontinuation
- 2010-04-27 CO CO10049265A patent/CO6280483A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100102098A (ko) | 2010-09-20 |
| EP2195297A1 (en) | 2010-06-16 |
| ZA201002092B (en) | 2011-11-30 |
| DOP2010000116A (es) | 2010-05-31 |
| RU2010119917A (ru) | 2011-11-27 |
| CN101827823B (zh) | 2012-10-03 |
| CA2699353A1 (en) | 2009-04-23 |
| SG185326A1 (en) | 2012-11-29 |
| CN101827823A (zh) | 2010-09-08 |
| MX2010004289A (es) | 2010-04-30 |
| AU2008312532A1 (en) | 2009-04-23 |
| US7943782B2 (en) | 2011-05-17 |
| MY153098A (en) | 2014-12-31 |
| CO6280483A2 (es) | 2011-05-20 |
| CR11386A (es) | 2010-08-18 |
| PA8800501A1 (es) | 2009-05-15 |
| US20090105486A1 (en) | 2009-04-23 |
| UA99487C2 (xx) | 2012-08-27 |
| WO2009052229A1 (en) | 2009-04-23 |
| BRPI0818343A2 (pt) | 2017-05-23 |
| JP2011500706A (ja) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121572T1 (el) | Σκευασμα δισκιου του ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου για χρηση στη θεραπεια κυστικης ινωσης | |
| CY1109084T1 (el) | Προϊον ζαχαροπλαστικης με χαμηλα λιπαρα | |
| NO20085243L (no) | Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting | |
| BRPI0607633A2 (pt) | mistura de oligossacarìdeo | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
| MX2018014298A (es) | Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida. | |
| AR065278A1 (es) | Sales de derivado de benzotiazol | |
| GT201000101A (es) | Productos quimioterapéuticos cristalinos | |
| GT201000099A (es) | Productos quimioterapéuticos cristalinos | |
| BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina | |
| BRPI0509903A (pt) | uso de compostos peptìdicos para profilaxia e tratamento da cefaléia crÈnica | |
| EP4214222A4 (en) | CLINICAL ASSAY OF CHIMERIC PROTEIN SIRP1A | |
| CY1114618T1 (el) | Βιολογικα δραστικα πεπτιδια που περιεχουν καρβοξυτελικη αργινινη | |
| MA32717B1 (fr) | Sels de n-[6-cis- (2.6-dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)- [1.1'-biphenyl]-3-carboxamide | |
| IL189286A0 (en) | Novel cysteine protease inhibitors and their therapeutic applications | |
| CY1112285T1 (el) | Υγρες φαρμακοτεχνικες μορφες αλατων 4-[2-(4-μεθυλφαινυλσουλφανυλ)φαινυλ]πιπεριδινης | |
| EA200702318A1 (ru) | Применение агомелатина для получения лекарственных средств, предназначенных для лечения синдрома смита-магениса | |
| DOP2010000112A (es) | Productos quimioterapeuticos cristalinos | |
| GT201000093A (es) | Productos quimioterapéuticos cristalinos | |
| ATE472316T1 (de) | Haarbehandlungszusammensetzungen | |
| GT200600141A (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos bipolares | |
| AR063895A1 (es) | Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de la leucomalacia periventricular | |
| UY31407A1 (es) | "productos quimioterapéuticos cristalinos" | |
| MX2018009558A (es) | Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina. |